AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...

in order to develop and commercialise Amylin’s existing portfolio of products, which has a main focus on the R&amp,D of treatments for patients with type 2 diabetes. AstraZeneca will pay Bristol ...

AstraZeneca Plc said its experimental obesity pill was well tolerated by patients with type-2 diabetes as it presented data from several studies testing its three new weight-loss medicines. The ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space.

AstraZeneca showcased positive early data on three experimental weight-loss drugs at ObesityWeek, highlighting its oral GLP-1 ...

This World Diabetes Day, DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing technology, is encouraging ...

The pharmaceutical giant expects overall sales and core earnings per share to rise by a high-teens percentage at constant ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

AstraZeneca said it is focussing on the combination potential of its weight-loss drug candidates with other molecules in its pipeline such as diabetes treatment Farxiga. The solid safety and ...

The South African Health Products Regulatory Authority ... are a class of medications that can help manage diabetes and ...

Eli Lilly said new results from a Phase 3 study of its tirzepatide showed weekly injections in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss, with nearly 99% ...